Metraipolis › archive › dc_f5c2eb7dc657

Double-dose furmonertinib for patients with osimertinib-resistant advanced NSCLC: therapeutic efficacy and safety — Europe PMC PMID:42180046

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42180046
DOI
10.3389/fonc.2026.1823078
License (as archived)
solo-consultazione
Archived
2026-11-02T15:46:39.506Z
SHA-256 of the archived text
e4837ca9feaea78239908cf77e7dd2510b987d6740fdbc1ae7c5bd6861deb9b6
Stable URL of this page
https://metraipolis.com/documento/dc_f5c2eb7dc657

How to cite

Double-dose furmonertinib for patients with osimertinib-resistant advanced NSCLC: therapeutic efficacy and safety — Europe PMC PMID:42180046 — Europe PMC (en), https://europepmc.org/article/MED/42180046 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_f5c2eb7dc657 (Metraipolis archive dc_f5c2eb7dc657, sha256 e4837ca9feaea78239908cf77e7dd2510b987d6740fdbc1ae7c5bd6861deb9b6)
BibTeX
@misc{dcf5c2eb7dc657,
  title = {Double-dose furmonertinib for patients with osimertinib-resistant advanced NSCLC: therapeutic efficacy and safety — Europe PMC PMID:42180046},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42180046},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_f5c2eb7dc657; sha256 e4837ca9feaea78239908cf77e7dd2510b987d6740fdbc1ae7c5bd6861deb9b6},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42180046. Agents can read the archived copy with the MCP tool read_document.